IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Study for the outcome and safety of individualized busulfan dosing with bortezomib for
 patients preparing for a second stem cell transplant to treat multiple myeloma.
Evaluation of six-month response in relapsed multiple myeloma subjects, who have had a prior
 autologous HSCT (greater than one year previously) receiving an IV busulfan-based
 conditioning regimen with the combination of pharmacokinetic (PK)-guided IV busulfan dosing
 and bortezomib, followed by a second autologous HSCT.

 Assessment of the safety profile of this conditioning regimen will also be completed.
Inclusion Criteria:

 1. Age 18 to 75 years, inclusive.

 2. Subjects must have multiple myeloma which requires treatment for relapsed disease and
 are eligible for the planned autologous HSCT.

 3. Subjects must have had one previous autologous HSCT, at least one year prior to the
 planned autologous HSCT in this study.

 4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.

 5. Negative beta-human chorionic gonadotropin (β-HCG) pregnancy test in all women of
 child-bearing potential.

 6. Subjects who are surgically sterile (ie, have undergone orchidectomy or hysterectomy);
 female subjects who have been postmenopausal for at least 12 consecutive months; or
 subjects who agree to remain abstinent or to practice double-barrier forms of birth
 control from trial screening through 30 days (for females) and 90 days (for males)
 from the last dose of the investigational medicinal product (IMP). If employing birth
 control, two of the following precautions must be used: vasectomy, tubal ligation,
 vaginal diaphragm, intrauterine device (IUD), birth control pill, birth control
 implant, condom, or sponge with spermicide.

 7. Subjects in whom the minimum stem cell dose of 2.0 x 10^6 cluster of differentiation
 34 (CD34)+ cells/kg has been collected.

 8. Ability to provide written informed consent prior to initiation of any study-related
 procedures, and ability, in the opinion of the Principal Investigator, to comply with
 all requirements of the study.

 Exclusion Criteria:

 1. Prior treatment history of allogeneic HSCT for any medical reason, not limited to
 myeloma treatment.

 2. Prior treatment history of more than one autologous HSCT or high-dose chemotherapy
 with stem cell rescue for any medical reason, not limited to myeloma treatment.

 3. Prior treatment with busulfan or gemtuzumab ozogamicin for any reason.

 4. Presence of a t(4;14) or p53 gene deletion as determined by fluorescence in situ
 hybridization (FISH) during the screening process or documented t(4; 14) or p53 gene
 deletion obtained during a time of active disease by any method.

 5. Systemic amyloidosis.

 6. Known allergy to boron or any components of bortezomib.

 7. Left ventricular ejection fraction (LVEF) < 45% as measured by either multi-gated
 acquisition scan (MUGA) or echocardiogram (ECHO) performed within 75 days prior to day
 of busulfan test dose. If cyclophosphamide was used for stem cell harvest, an ECHO or
 MUGA must be done prior to enrollment to confirm adequate cardiac function.

 8. Uncontrolled arrhythmia or symptomatic cardiac disease at the time of screening.

 9. Symptomatic pulmonary disease, based on Forced Expiratory Volume in 1 Second (FEV1),
 Forced Vital Capacity (FVC) or Diffusing Capacity of the Lung for Carbon Monoxide
 (DLCO) < 50% of predicted (corrected for hemoglobin) measured within 75 days prior to
 day of busulfan test dose.

 10. Aspartate transaminase (AST)/alanine transaminase (ALT) ≥ 3 x the upper limit of
 normal (ULN),

 11. History of elevated total serum bilirubin >2 mg/dL that had been caused by previous
 chemotherapy at any point, or total bilirubin > 2.0 mg/dL at the time of screening
 with the exception of Gilbert's disease.

 12. Hepatic synthetic dysfunction evident International Normalized Ratio (INR) ≥ 2.0 at
 the time of screening.

 13. Any previous history of fulminant liver failure, cirrhosis, alcoholic hepatitis,
 esophageal varices, hepatic encephalopathy, ascites related to portal hypertension,
 bacterial or fungal liver abscess, biliary obstruction, and symptomatic biliary
 disease.

 14. Prior total body irradiation therapy or radiation therapy directly applied to the
 liver.

 15. Known history of or current hepatitis B, hepatitis C, HIV, or uncontrolled active
 infection of any kind at the time of test dose. If serology antibody studies are
 positive, a quantitative polymerase chain reaction (PCR) must be completed to confirm
 lack of active infection.

 16. Serum creatinine >2.0 mg/dL at the time of Screening.

 17. ≥ Grade 1 neuropathy with pain, or > Grade 2 neuropathy without pain (subjects with
 neuropathy caused by a previous regimen that is recovered to ≤ Grade 2 and stable
 without pain may be included).

 18. Women who are pregnant or lactating.

 19. Current or history of drug and/or alcohol abuse.

 20. Use of other investigational therapies within 30 days